Boglárka Pósfai1, Levente Kuthi2, Linda Varga1, Ibolya Laczó3, János Révész4, Réka Kránicz1, Anikó Maráz5. 1. Department of Oncotherapy, University of Szeged, Szeged, Hungary. 2. Department of Pathology, University of Szeged, Szeged, Hungary. 3. Pándy Kálmán Hospital Gyula, Gyula, Hungary. 4. Institute of Radiotherapy and Clinical Oncology, Borsod County Hospital and University Academic Hospital, Miskolc, Hungary. 5. Department of Oncotherapy, University of Szeged, Szeged, Hungary dr.aniko.maraz@gmail.com.
Abstract
BACKGROUND: Neuroendocrine neoplasms include a heterogeneous group of malignant tumors. Primary neuroendocrine tumors in the genitourinary tract are rare, comprising approximately 1-2% of genitourinary malignancies. MATERIALS AND METHODS: An extensive search was performed for publications between 2000 and 2018 regarding neuroendocrine tumors of the genitourinary tract. Epidemiological, clinical, histopathological, prognostic and therapeutic data were evaluated. RESULTS: Neuroendocrine tumors of the kidneys are exceedingly rare, mostly well-differentiated. 0.5-1% of all primary bladder malignancies are small cell neuroendocrine carcinomas. Characteristically, prostatic adenocarcinoma with neuroendocrine differentiation occurs in androgen receptor-independent/castrate-resistant cancer. Small cell and large cell neuroendocrine carcinomas are the most aggressive tumors in each location. CONCLUSION: Due to the rarity and poor prognosis of these tumors, proper pathological diagnosis and early therapy are important. Therapeutic guidelines are not available. Surgery, radiotherapy and/or chemotherapy are possible treatment options; somatostatin analogs are used as standard therapy in case of well-differentiated neuroendocrine tumors. Copyright
BACKGROUND:Neuroendocrine neoplasms include a heterogeneous group of malignant tumors. Primary neuroendocrine tumors in the genitourinary tract are rare, comprising approximately 1-2% of genitourinary malignancies. MATERIALS AND METHODS: An extensive search was performed for publications between 2000 and 2018 regarding neuroendocrine tumors of the genitourinary tract. Epidemiological, clinical, histopathological, prognostic and therapeutic data were evaluated. RESULTS:Neuroendocrine tumors of the kidneys are exceedingly rare, mostly well-differentiated. 0.5-1% of all primary bladder malignancies are small cell neuroendocrine carcinomas. Characteristically, prostatic adenocarcinoma with neuroendocrine differentiation occurs in androgen receptor-independent/castrate-resistant cancer. Small cell and large cell neuroendocrine carcinomas are the most aggressive tumors in each location. CONCLUSION: Due to the rarity and poor prognosis of these tumors, proper pathological diagnosis and early therapy are important. Therapeutic guidelines are not available. Surgery, radiotherapy and/or chemotherapy are possible treatment options; somatostatin analogs are used as standard therapy in case of well-differentiated neuroendocrine tumors. Copyright
Authors: Kedar G Sharbidre; Ajaykumar C Morani; Mohd Zahid; Priya Bhosale; Chandana Lall; Isaac R Francis; Sadhna Verma Journal: Abdom Radiol (NY) Date: 2022-04-12
Authors: Borivoj Golijanin; Boris Gershman; Andre De Souza; Ohad Kott; Benedito A Carneiro; Anthony Mega; Dragan J Golijanin; Ali Amin Journal: Front Oncol Date: 2021-04-22 Impact factor: 6.244
Authors: Giuseppe Lamberti; Maria Pia Brizzi; Sara Pusceddu; Fabio Gelsomino; Giovanni Di Meglio; Francesco Massari; Giuseppe Badalamenti; Ferdinando Riccardi; Toni Ibrahim; Chiara Ciccarese; Sebastiano Buti; Carlo Carnaghi; Natalie Prinzi; Francesco Panzuto; Davide Campana Journal: J Clin Med Date: 2020-05-05 Impact factor: 4.241